Anthropic's Claude AI discovers novel enzyme system with CRISPR-like repeats
AI identifies previously unknown genetic structure in bacteriophages, opening new research avenues.
1Breakthrough phage discovery
Anthropic's Claude AI identified a new enzyme system in bacteriophages featuring CRISPR-like DNA repeats. The system, named ART (array-associated reverse transcriptases), consists of three components: a reverse transcriptase enzyme, a partner gene, and regularly spaced DNA repeats. Unlike CRISPR systems, ART lacks adjacent cas genes. This marks the first major finding from Anthropic's new molecular biology research group, though the system's exact function remains unknown.
2Unconventional research approach
Claude AI autonomously analyzed 1.9 billion protein clusters over 21.5 hours without human intervention, using 949 agent sessions processing 215.6 million tokens. The AI identified 200,000 enzyme clusters and scored 3,564 candidate partner families before selecting 19 reports for human review. The ART discovery emerged when an agent noticed repeat patterns 'by eye' in raw DNA data, then systematically compared them against known systems before filing its report.
3Technical validation challenges
The discovery proved difficult to replicate - in 10 subsequent attempts, the AI consistently missed the array. In controlled tests, Anthropic's top models identified the array 90% of time when given direct DNA access, but success dropped to 32% when working through files and tools. The team observed specific neural signals in Claude's architecture that fired just before repeat recognition, offering insights into the AI's decision-making process.
4Scientific community response
CRISPR pioneer Feng Zhang reviewed the findings, calling the RNA-repeat arrays 'genuinely intriguing' and worthy of further study. While the reverse transcriptase enzyme itself was known, Claude appears first to identify its association with the repeat array and partner protein. Earlier genome studies of ART phages had documented the enzyme but overlooked these accompanying elements.
5Biological significance
In lab tests, the ART array produced distinct short RNAs constituting up to 8% of phage RNA 15 minutes post-infection. While the enzyme's activity remains unconfirmed, all known systems with similar features can cut, copy or paste DNA. The discovery adds to our understanding of bacteriophage genetics and potential new genetic engineering tools.
6Anthropic's research infrastructure
The discovery comes from Anthropic's new life sciences unit, established in spring 2026 with a Bay Area lab operating at biosafety levels 1-2. The $400 million acquisition of Coefficient Bio in April and launch of Claude Science in June expanded their capabilities. Researchers use Claude Code and Claude Science for all lab work, with human scientists conducting physical experiments.
7Industry context
The breakthrough occurs alongside OpenAI's launch of GPT-Rosalind, another AI model targeting life sciences research. Anthropic's approach differs by combining AI analysis with wet lab validation. The company is now soliciting external research proposals to further investigate ART's functions, positioning itself at the intersection of AI and biotechnology innovation.
8Future research directions
Anthropic has initiated additional experiments to determine ART's biological function. The discovery's difficulty to replicate highlights both the promise and challenges of AI-driven research. As AI systems like Claude demonstrate capability to identify novel biological patterns, they may accelerate discovery while requiring new validation frameworks to ensure scientific rigor in autonomous research processes.